Elizabeth H. Weatherman
Elizabeth H. Weatherman's purchase track record
Elizabeth H. Weatherman has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/3/2026 | PODD | $497K | +3.4% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Insulet Sets Q3 2026 Earnings Date for Nov 4. Insulet has scheduled its third-quarter 2026 financial results for release on November 4, 2026. Recent commentary suggests the company offers affordable growth supported by strong fundamentals. The stock is currently trading near its 52-week low, with technical indicators showing a support rejection and volume spike.
Transaction History
| RPRX | ▲ Buy | Grant | 4,545 | $0 | 6/5/2026 | View on chart |
| PODD | ▲ Buy | Open Market | 3,450 | $497K | 6/3/2026 | View on chart |
| PODD | ▲ Buy | Grant | 1,660 | $0 | 5/20/2026 | View on chart |
| RPRX | ▲ Buy | Grant | 5,806 | $0 | 7/31/2025 | View on chart |
| RPRX | ▲ Buy | Grant | 2,752 | $0 | 7/31/2025 | View on chart |
| PODD | ▲ Buy | Grant | 778 | $0 | 5/22/2025 | View on chart |
| PODD | ▲ Buy | Grant | 1,380 | $0 | 5/22/2024 | View on chart |
| PODD | ▲ Buy | Grant | 843 | $0 | 5/23/2023 | View on chart |
| PODD | ▲ Buy | Grant | 1,009 | $0 | 5/24/2022 | View on chart |
| PODD | ▲ Buy | Grant | 1,232 | $0 | 2/4/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Royalty Pharma Declares Q4 2026 Dividend
Royalty Pharma announced its fourth-quarter 2026 dividend, a routine move that supports its status as a consistent income provider with a yield near 3%. Recent commentary also highlights the company's valuation metrics, noting that its multiples may offer an attractive risk-reward balance for some market participants. The stock currently trades within its 52-week range, with analysts maintaining a consensus target price above current levels.
Royalty Pharma Declares Q4 2026 Dividend. Royalty Pharma announced its fourth-quarter 2026 dividend, a routine move that supports its status as a consistent income provider with a yield near 3%. Recent commentary also highlights the company's valuation metrics, noting that its multiples may offer an attractive risk-reward balance for some market participants. The stock currently trades within its 52-week range, with analysts maintaining a consensus target price above current levels.